ABSTRACT

Nat Cancer. 2022 Jan;3(1):11-24. doi: 10.1038/s43018-021-00319-0. Epub 2022 Jan 20.

The current landscape of immunotherapy for pediatric brain tumors.

Hwang El(1), Sayour EJ(2), Flores CT(2), Grant G(3), Wechsler-Reya R(4), Hoang-Minh LB(2), Kieran MW(5), Salcido J(6), Prins RM(7), Figg JW(2), Platten M(8), Candelario KM(2), Hale PG(9), Blatt JE(2), Governale LS(2), Okada H(10), Mitchell DA(2), Pollack IF(11).

Author information:

(1)Division of Oncology, Brain Tumor Institute, Children's National Hospital, Washington, DC, USA. ehwang@childrensnational.org.

(2)Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, FL, USA.

(3) Division of Pediatric Neurosurgery, Lucile Packard Children's Hospital,

Stanford University, Palo Alto, CA, USA.

(4)Tumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

(5)Day One Biopharmaceuticals, San Francisco, CA, USA.

(6)Brain Tumor Foundation, Ashville, NC, USA.

(7)Departments of Neurosurgery and Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

(8)Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University and CCU Brain Tumor Immunology, DKFZ, Heidelberg, Germany. (9)Children's Brain Trust, Coral Springs, FL, USA.

(10)Department of Neurosurgery, University of California, San Francisco, CA, USA.

(11)Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Pediatric central nervous system tumors are the most common solid malignancies in childhood, and aggressive therapy often leads to long-term sequelae in survivors, making these tumors challenging to treat. Immunotherapy has revolutionized prospects for many cancer types in adults, but the intrinsic complexity of treating pediatric patients and the scarcity of clinical studies of children to inform effective approaches have hampered the development of effective immunotherapies in pediatric settings. Here, we review recent advances and ongoing challenges in pediatric brain cancer immunotherapy, as well as considerations for efficient clinical translation of efficacious immunotherapies into pediatric settings.

© 2022. Springer Nature America, Inc.

DOI: 10.1038/s43018-021-00319-0 PMID: 35121998